Cited by 386Viral Infectious Diseases and Gene Expression in InsectsProtein purification and stabilityTransgenic Plants and Applications

Expression systems for therapeutic glycoprotein production

Durocher, Yves, Butler, Michael·2009·Current Opinion in Biotechnology

Abstract

There are slightly over 165 recombinant pharmaceuticals currently approved for human use. Another 500 protein candidates are in preclinical and clinical development, about 70% of these being glycosylated proteins. The need for expression systems allowing the efficient manufacturing of high quality glycoproteins is thus becoming imperative. Recent developments with CHO cells, the predominant mammalian expression system, have focused on either increasing cell specific productivity or prolonging the life span of cells in culture that translates to high integrated viable cell densities. These two factors have allowed volumetric productivities in excess of 5 g/L under conditions of controlled nutrient feeding. In addition to glycoengineering strategies, which are offering considerable advantage in producing proteins with enhanced therapeutic properties, several alternative expression systems are being developed for their manufacture, each with their advantages and limitations.

Integrity signals

Registry

Crossref · 10.1016/j.copbio.2009.10.008

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Different gene amplification systems developed and used in CHO cells allow high titer yields and good specific productivity.

    “Moreover, different gene amplification systems have been developed and used in CHO cells, which allow for high titer yields and good specific productivity (Durocher and Butler, 2009;Kim et al., 2012;Lai et al., 2013).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009

  • Among mammalian-based expression systems, CHO cells are by far the most commonly used cell line.

    “Among the mammalian-based expression systems, CHO cells is by far, the most commonly used cell line.”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009

  • CHO cells are involved in the production of over 70% of recombinant biopharmaceutical proteins, most of them monoclonal antibodies.

    “It is involved in the production of over 70% of recombinant biopharmaceutical proteins, most of them being monoclonal antibodies (mAbs) (Durocher and Butler, 2009;Kim et al., 2012;Butler and Spearman, 2014).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009

  • Transgenic animals often produce different glycosylation patterns compared to native human proteins.

    “As with other mammalian expression systems, transgenic animals often produce different glycosylation pattern compared to native human proteins (Durocher and Butler, 2009).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009

  • Only two marketed recombinant glycoproteins are currently manufactured in BHK cells, Factor VIIa and Factor VIII.

    “Only two marketed recombinant glycoproteins are currently manufactured in these cells, Factor VIIa (NovoSeven ® ) and Factor VIII (Kogenate ® and Kovaltry ® ), which are other clotting factors (Durocher and Butler, 2009;Dumont et al., 2015).”

    From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Durocher, Y., & Butler, M.
Affiliations
  • Biotechnology Research Institute (CA)
  • University of Manitoba (CA)
Corresponding author
  • Durocher, Yves
  • Butler, Michael
Venue
Current Opinion in Biotechnology
Publisher
Elsevier BV
Published
2009-12
Volume
20
Issue
6
Pages
700-707
ISSN
0958-1669 (ISSN-L)
OpenAlex
W1994251377
Cited by
386
References
3
Citations by year
2026: 8 · 2025: 9 · 2024: 14 · 2023: 13 · 2022: 10 · 2021: 23 · 2020: 15 · 2019: 31 · 2018: 27 · 2017: 30 · 2016: 15 · 2015: 33 · 2014: 31 · 2013: 36 · 2012: 41
FWCI
2.29
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Biotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • NPARC (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
Keywords
recombinant protein expression systems, therapeutic glycoproteins, CHO cells, glycosylation, glycoengineering, cell-specific productivity, cell lifespan, nutrient feeding, volumetric productivity, biopharmaceutical manufacturing
MeSH terms
Animals, Biopharmaceutics, Cell Survival, Chemistry, Pharmaceutical, Cricetulus, Glycoproteins, Cricetinae, Humans, Insecta, Plants, Recombinant Proteins, Drug Design, Protein Engineering, CHO Cells, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review